Research Vision

Mucosis strives to discover innovative mucosal vaccines that are more efficacious and user-friendly by translating excellent scientific research into a robust vaccine technology which we use to create better, painless and needle-free vaccines to combat viral, bacterial and parasitic pathogens. We are dedicated to achieving these goals by motivating talented researchers to excel and by collaborating with the best academic and industrial partners in the world.

research vision

15.11.11 Mucosis announces new scientific advisory board
more >

17.05.11 Mucosis appoints Thomas Johnston as Chief Business Officer
more >

21.03.11 Mucosis starts clinical study with its lead product, Flugem®
more >

12.11.10 Dr. Barry Buckland joins the Mucosis supervisory board
more >

28.09.10 Mucosis B.V. and PATH sign agreement to pursue Mimopath®-based oral diarrhea vaccines
more >